Lung cancer test kit

colorectal canceroncologyfor KRAS mutations

[Intended use] About 30% of various cancer patients harbor KRAS somatic mutations, such as 30-40% in colorectal cancer, 2-10% in non-small cell lung cancer and 90% in pancreatic cancer. In addition, 90% of all the mutations concentrate on 12 and 13 codons in exon 2. Importantly, cancer patents with KRAS mutations do not respond well to tyrosine kinase inhibitor therapy of Iressa, Tarceva, Erbitux and Vectibix, indicating the impact of the mutation status in therapy selection. This kit detects seven common mutations in exon 2 of the KRAS gene with a total frequency >90% (Table 1). The kits can be used for 1) early screening and early diagnosis of cancer, 2) early monitoring of cancer relapse, and 3) selection of targeted therapy. [Detection principle] This kit uses pyrophosphorolysis activated polymerization (PAP ) technology to specifically amplify the mutant DNA but not wildtype DNA molecules. The amplified product is measured in real time fluorescence format. [Samples] Fresh and frozen tissues, paraffin-embedded tissues, plasma and urine. [Advantages] 1. High sensitivity: ability to detect a single copy of KRAS mutations. 2. High specificity: virtually no false positive amplifications even in the presence of heavy background of wildtype DNA. 3.Freeze-dried format: much earlier and user-friendly manipulation. 4. Non-invasive sampling: plasma and urine samples can be applied.